"Major setback! We have been set up for the last year for a sale but are now just where RVX was many years ago. It will take many years and raising a lot more cash probably to get anywhere."

There are many ways this could play out. Keep in mind that in the coming months, Resverlogix's BETonMACE will be revealing top-line and full data, and that Zenith Capital Corp holds the Resverlogix Royalty Preferred Shares (RPSs). With positive BETonMACE results, there could very well be a ripple effect to Zenith. In a general sense, a successful BETonMACE trial will validate the potential of epigenetic therapies and more specifically the BET inhibitor platform of Resverlogix and Zenith, since Zenith was split off from Resverlogix. Plus, Zenith has an ongoing Phase 2 metastatic castrate resistant prostate cancer trial with promising results thus far that should be completing and reporting results soon. The Zenith/Pfizer TNBP trial is likely too early stage right now to have any near term relevance. One or a combination of the above could still lead to a sale of ZEL and/or ZCC. Personally, I like the idea of splitting off ZEL for a listing or a sale so that I still own shares of ZCC and the RPSs.

BearDownAZ